Pazopanib for the treatment of renal cancer

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1171-1189

  Rini, Brian ^a   Al Marrawi, Mhd Yaser ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

GW786034; pazopanib; renal cell carcinoma; tyrosine kinase inhibitor; VEGF; VEGFR TKI

Indexed keywords

BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; PAZOPANIB; PLACEBO; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADVANCED CANCER; ALGORITHM; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DEPIGMENTATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAIR DEPIGMENTATION; HAIR DISEASE; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LARGE INTESTINE PERFORATION; LEUKOPENIA; LIVER TOXICITY; LUNG THROMBOSIS; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOSIS; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VOMITING;

EID: 79953864160     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.571206     Document Type: Article

References (59)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
2. Linehan WM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170(6 Pt 1):2163-72 (Pubitemid 37413950)
3. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004 (Pubitemid 46646218)
4. Linehan WM, Zbar B, Bates BE, et al. Cancer of the kidney and ureter. In: deVita VTHS, Rosenberg SA, editors, Cancer principles and practice of oncology. 6th edition. Lippincott Williams and Wilkins, Philadelphia, PA; 2001. p. 1362-96
5. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-90 (Pubitemid 41770167)
6. Fisher RIRS, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S55-7
7. Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009;115(S10):2306-12
8. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90 (Pubitemid 24232386)
9. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear-cell renal cell carcinoma. J Pathol 2002;196(2):186-93 (Pubitemid 34110900)
10. Gallou C, Joly D, Méjean A, et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999;13(6):464-75 (Pubitemid 29270017)
11. Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009;9(12):1793-805
12. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743-8
13. Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001;37(17):2199-203 (Pubitemid 33001289)
14. Wechsel HWBK, Feil G, Loeser W, et al. Renal cell carcinoma: relevance of angiogenetic factors. Anticancer Res 1999;19(2C):1537-40 (Pubitemid 29255642)
15. Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol 2009;5(5):703-12
16. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006;63(5):601-15
17. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34 (Pubitemid 36910021)
18. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144-50
19. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43
20. Raymond E, Faivre S, Vera K, et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003;22:192
21. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72 (Pubitemid 46202316)
22. Rini BIWG, Hudes G, Stadler WM, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):5032
23. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15(12):4220-7
24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
25. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
26. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
27. Limvorasak S, Posadas EM. Pazopanib: therapeutic developments. Expert Opin Pharmacother 2009;10(18):3091-102
28. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs Today (Barc) 2009;45(9):651-61
29. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21 (Pubitemid 47052491)
30. Shibata SLJ, Chung VM, Lenz H, et al. A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). J Clin Oncol 2010;28(15S):abstract 2571
31. Dejonge MSS, Verweij J, Collins TS, et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol 2006;24(142S):abstract 3088
32. Tan ARJS, Dowlati A, Levinson K, et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J Clin Oncol 2008;26(20 Suppl):abstract 3552
33. Hutson TE, Davis ID, Machiels J-PH, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28(3):475-80
34. Suttle B, Ball HA, Molimard M, et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15S):abstract 3048
35. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
36. Sternberg CN. Pazopanib in renal cell carcinoma. Clin Adv Hematol Oncol 2010;8(4):232-3
37. Xu C-F, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British Journal of Cancer 2010;102(9):1371-7
38. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530
39. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23(4):832-41 (Pubitemid 46224183)
40. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
41. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
42. DePrimo S, Bello C, Smeraglia J, et al. Soluble protein biomarkers of pharmacodynamic activity of the multi-targeted kinase inhibitor SU11248 in patients with metastatic renal cell cancer. Proc Am Assoc Cancer Res 2005;46:108
43. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
44. Votrient (pazopanib) [package insert] Research Triangle Park, NC: GlaxoSmithKline; October 2009
45. Votrient. Drug Facts and Comparisons. Facts & Comparisons® eAnswers [online]. 2010. Available from: http://www.tuftshealthplan.com/ providers/pdf/pharmacy-criteria/votrient. pdf Wolters Kluwer Health, Inc [Accessed 1 February 2010]
46. Lang JM, Harrison MR. Pazopanib for the treatment of patients with advanced cell carcinoma. Clin Med Insights Oncol 2010;4:95-105
47. ClinicalTrials.gov online. Available from: http://clinicaltrials.gov/
48. Selleckchem.com online. Available from: http://www.selleckchem.com/
49. Varella L, Rini BI. Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs 2010;15(3):343-53
50. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 373:1119-32
51. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib maleate (SU11248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (RCC). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):LBA3
52. Mischinger J, Froehlich E. Prognostic relevance of B7H1 and B7H3 protein expressions in metastatic clear cell renal cell carcinoma. ASCO 2010 Abstract e15074 from Department of Urology, Medical University of Graz, Graz, Austria; Center for Medical Research
53. Kim JJ, Vaziri SA, Elson P, Rini BI. General Poster Session, Genitourinary CancerASCO 2010 [abstract No: 4629]. J Clin Oncol 2010;28(15S):abstract 4629
54. Hainsworth JD, Spigel DR. A phase II trial of pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab [abstract]. ASCO 2010
55. Ball HA, Xu C, Sternberg CN. Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma [abstract 4520]. ASCO 2010; GlaxoSmithKline
56. Tran HT, Liu Y, Lin Y. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients [abstract 4522]. ASCO 2010
57. Kim JJ, Vaziri SA, Elson P, Rini BI. VEGF single nucleotide polymorphisms (SNPs) and correlation to baseline and sunitinib-induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract 330]. ASCO 2010
58. Sternberg CN. Randomised, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC), ESMO: Pazopanib in advanced MRCC-late breaker published 11/10/2010 by ecancer reporter Jo Armstrong
59. Xu CF, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. [PubMed: PMID: 21145803; J Hepatology 2011 Feb 12; Published by Elsevier B.V]